ID   IMDH1_HUMAN             Reviewed;         514 AA.
AC   P20839; A4D0Z6; A4D0Z7; A6NDW5; A6NNI6; B3KNP7; B3KVM8; B4DE09;
AC   C9JV30; J3KNX8; Q8N194; Q96NU2;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   08-NOV-2002, sequence version 2.
DT   15-MAR-2017, entry version 204.
DE   RecName: Full=Inosine-5'-monophosphate dehydrogenase 1 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMP dehydrogenase 1 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMPD 1 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMPDH 1 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            EC=1.1.1.205 {ECO:0000255|HAMAP-Rule:MF_03156};
DE   AltName: Full=IMPDH-I;
GN   Name=IMPDH1 {ECO:0000255|HAMAP-Rule:MF_03156}; Synonyms=IMPD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=1969416;
RA   Natsumeda Y., Ohno S., Kawasaki H., Konno Y., Weber G., Suzuki K.;
RT   "Two distinct cDNAs for human IMP dehydrogenase.";
RL   J. Biol. Chem. 265:5292-5295(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3; 4 AND 5).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-11, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND
RP   ENZYME REGULATION.
RX   PubMed=7903306;
RA   Carr S.F., Papp E., Wu J.C., Natsumeda Y.;
RT   "Characterization of human type I and type II IMP dehydrogenases.";
RL   J. Biol. Chem. 268:27286-27290(1993).
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RX   PubMed=15028279; DOI=10.1016/j.ygeno.2003.09.023;
RA   Jin P., Fu G.K., Wilson A.D., Yang J., Chien D., Hawkins P.R.,
RA   Au-Young J., Stuve L.L.;
RT   "PCR isolation and cloning of novel splice variant mRNAs from known
RT   drug target genes.";
RL   Genomics 83:566-571(2004).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=7763314; DOI=10.1016/0006-2952(95)00026-V;
RA   Hager P.W., Collart F.R., Huberman E., Mitchell B.S.;
RT   "Recombinant human inosine monophosphate dehydrogenase type I and type
RT   II proteins. Purification and characterization of inhibitor binding.";
RL   Biochem. Pharmacol. 49:1323-1329(1995).
RN   [10]
RP   SUBCELLULAR LOCATION, AND NUCLEIC ACID-BINDING.
RX   PubMed=14766016; DOI=10.1042/BJ20031585;
RA   McLean J.E., Hamaguchi N., Belenky P., Mortimer S.E., Stanton M.,
RA   Hedstrom L.;
RT   "Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro
RT   and in vivo.";
RL   Biochem. J. 379:243-251(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-160, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOG.
RA   Risal D., Strickler M.D., Goldstein B.M.;
RT   "Crystal structure of the human type I inosine monophosphate
RT   dehydrogenase and implications for isoform specificity.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [14]
RP   VARIANT RP10 PRO-224.
RX   PubMed=11875049; DOI=10.1093/hmg/11.5.547;
RA   Kennan A., Aherne A., Palfi A., Humphries M., McKee A., Stitt A.,
RA   Simpson D.A., Demtroder K., Orntoft T., Ayuso C., Kenna P.F.,
RA   Farrar G.J., Humphries P.;
RT   "Identification of an IMPDH1 mutation in autosomal dominant retinitis
RT   pigmentosa (RP10) revealed following comparative microarray analysis
RT   of transcripts derived from retinas of wild-type and Rho(-/-) mice.";
RL   Hum. Mol. Genet. 11:547-557(2002).
RN   [15]
RP   VARIANTS RP10 ASN-226 AND ILE-268.
RX   PubMed=11875050; DOI=10.1093/hmg/11.5.559;
RA   Bowne S.J., Sullivan L.S., Blanton S.H., Cepko C.L., Blackshaw S.,
RA   Birch D.G., Hughbanks-Wheaton D., Heckenlively J.R., Daiger S.P.;
RT   "Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1)
RT   cause the RP10 form of autosomal dominant retinitis pigmentosa.";
RL   Hum. Mol. Genet. 11:559-568(2002).
RN   [16]
RP   VARIANTS RP10 MET-116; ASN-226; ILE-268 AND PRO-372, VARIANTS LCA11
RP   TRP-105 AND LYS-198, VARIANTS THR-285 AND ASP-324, CHARACTERIZATION OF
RP   VARIANTS RP10 MET-116 AND PRO-372, CHARACTERIZATION OF VARIANTS LCA11
RP   TRP-105 AND LYS-198, AND CHARACTERIZATION OF VARIANT ASP-324.
RX   PubMed=16384941; DOI=10.1167/iovs.05-0868;
RA   Bowne S.J., Sullivan L.S., Mortimer S.E., Hedstrom L., Zhu J.,
RA   Spellicy C.J., Gire A.I., Hughbanks-Wheaton D., Birch D.G.,
RA   Lewis R.A., Heckenlively J.R., Daiger S.P.;
RT   "Spectrum and frequency of mutations in IMPDH1 associated with
RT   autosomal dominant retinitis pigmentosa and Leber congenital
RT   amaurosis.";
RL   Invest. Ophthalmol. Vis. Sci. 47:34-42(2006).
CC   -!- FUNCTION: Catalyzes the conversion of inosine 5'-phosphate (IMP)
CC       to xanthosine 5'-phosphate (XMP), the first committed and rate-
CC       limiting step in the de novo synthesis of guanine nucleotides, and
CC       therefore plays an important role in the regulation of cell
CC       growth. Could also have a single-stranded nucleic acid-binding
CC       activity and could play a role in RNA and/or DNA metabolism. It
CC       may also have a role in the development of malignancy and the
CC       growth progression of some tumors.
CC   -!- CATALYTIC ACTIVITY: Inosine 5'-phosphate + NAD(+) + H(2)O =
CC       xanthosine 5'-phosphate + NADH. {ECO:0000255|HAMAP-Rule:MF_03156}.
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03156};
CC   -!- ENZYME REGULATION: Mycophenolic acid (MPA) is a non-competitive
CC       inhibitor that prevents formation of the closed enzyme
CC       conformation by binding to the same site as the amobile flap. In
CC       contrast, mizoribine monophosphate (MZP) is a competitive
CC       inhibitor that induces the closed conformation. MPA is a potent
CC       inhibitor of mammalian IMPDHs but a poor inhibitor of the
CC       bacterial enzymes. MZP is a more potent inhibitor of bacterial
CC       IMPDH. Subject to product inhibition by XMP and NADH. Also
CC       inhibited by ADP. {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:7903306}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for Inosine 5'-phosphate {ECO:0000269|PubMed:7763314,
CC         ECO:0000269|PubMed:7903306};
CC         KM=46 uM for NAD(+) {ECO:0000269|PubMed:7763314,
CC         ECO:0000269|PubMed:7903306};
CC   -!- PATHWAY: Purine metabolism; XMP biosynthesis via de novo pathway;
CC       XMP from IMP: step 1/1. {ECO:0000255|HAMAP-Rule:MF_03156}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:7903306, ECO:0000269|Ref.13}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:14766016}. Nucleus {ECO:0000255|HAMAP-
CC       Rule:MF_03156, ECO:0000269|PubMed:14766016}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P20839-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P20839-2; Sequence=VSP_002674;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P20839-3; Sequence=VSP_014363;
CC       Name=4;
CC         IsoId=P20839-4; Sequence=VSP_043485;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P20839-5; Sequence=VSP_046969;
CC         Note=Ref.2 (BAG53840) sequence has a frameshift in position 35.;
CC       Name=6;
CC         IsoId=P20839-6; Sequence=VSP_046970;
CC         Note=No experimental confirmation available.;
CC       Name=7;
CC         IsoId=P20839-7; Sequence=VSP_046968;
CC   -!- TISSUE SPECIFICITY: IMP type I is the main species in normal
CC       leukocytes and type II predominates over type I in the tumor.
CC   -!- INDUCTION: Constitutively expressed.
CC   -!- DISEASE: Retinitis pigmentosa 10 (RP10) [MIM:180105]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. {ECO:0000269|PubMed:11875049,
CC       ECO:0000269|PubMed:11875050, ECO:0000269|PubMed:16384941}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Leber congenital amaurosis 11 (LCA11) [MIM:613837]: A
CC       severe dystrophy of the retina, typically becoming evident in the
CC       first years of life. Visual function is usually poor and often
CC       accompanied by nystagmus, sluggish or near-absent pupillary
CC       responses, photophobia, high hyperopia and keratoconus.
CC       {ECO:0000269|PubMed:16384941}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Because IMPDH activity is tightly linked with cell
CC       proliferation, it has been recognized as a target for cancer and
CC       viral chemotherapy and as a target for immunosuppressive drugs.
CC       The activities of the antitumor drug tiazofurin, the antiviral
CC       drug ribavirin, and the immunosuppressive drugs mizoribine and
CC       mycophenolic acid (MPA) are attributed to the inhibition of IMPDH.
CC       In addition, bacterial and parasitic IMPDH's differ significantly
CC       from mammalian enzymes, which makes it a suitable target for anti-
CC       infective drugs.
CC   -!- SIMILARITY: Belongs to the IMPDH/GMPR family. {ECO:0000255|HAMAP-
CC       Rule:MF_03156}.
CC   -!- WEB RESOURCE: Name=Mutations of the IMPDH1 gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/impdhmut.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05272; AAA36114.1; -; mRNA.
DR   EMBL; AK054640; BAB70780.1; -; mRNA.
DR   EMBL; AK054667; BAG51409.1; -; mRNA.
DR   EMBL; AK122994; BAG53840.1; ALT_FRAME; mRNA.
DR   EMBL; AK293413; BAG56920.1; -; mRNA.
DR   EMBL; AC010655; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236947; EAL24310.1; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24311.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83652.1; -; Genomic_DNA.
DR   EMBL; BC033622; AAH33622.2; -; mRNA.
DR   EMBL; CD014008; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS34748.1; -. [P20839-3]
DR   CCDS; CCDS34749.1; -. [P20839-6]
DR   CCDS; CCDS43643.1; -. [P20839-5]
DR   CCDS; CCDS47699.1; -. [P20839-7]
DR   CCDS; CCDS47700.1; -. [P20839-2]
DR   CCDS; CCDS55161.1; -. [P20839-4]
DR   PIR; A35566; A35566.
DR   RefSeq; NP_000874.2; NM_000883.3. [P20839-6]
DR   RefSeq; NP_001096075.1; NM_001102605.1. [P20839-5]
DR   RefSeq; NP_001136045.1; NM_001142573.1. [P20839-1]
DR   RefSeq; NP_001136046.1; NM_001142574.1. [P20839-4]
DR   RefSeq; NP_001136047.1; NM_001142575.1. [P20839-2]
DR   RefSeq; NP_001136048.1; NM_001142576.1. [P20839-7]
DR   RefSeq; NP_001291450.1; NM_001304521.1.
DR   RefSeq; NP_899066.1; NM_183243.2. [P20839-3]
DR   RefSeq; XP_016867661.1; XM_017012172.1.
DR   UniGene; Hs.654401; -.
DR   PDB; 1JCN; X-ray; 2.50 A; A/B=1-514.
DR   PDBsum; 1JCN; -.
DR   ProteinModelPortal; P20839; -.
DR   SMR; P20839; -.
DR   BioGrid; 109827; 79.
DR   DIP; DIP-60163N; -.
DR   IntAct; P20839; 16.
DR   MINT; MINT-2801694; -.
DR   STRING; 9606.ENSP00000345096; -.
DR   BindingDB; P20839; -.
DR   ChEMBL; CHEMBL1822; -.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01024; Mycophenolic acid.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00811; Ribavirin.
DR   DrugBank; DB06103; VX-148.
DR   GuidetoPHARMACOLOGY; 2624; -.
DR   iPTMnet; P20839; -.
DR   PhosphoSitePlus; P20839; -.
DR   BioMuta; IMPDH1; -.
DR   DMDM; 25014074; -.
DR   EPD; P20839; -.
DR   MaxQB; P20839; -.
DR   PaxDb; P20839; -.
DR   PeptideAtlas; P20839; -.
DR   PRIDE; P20839; -.
DR   Ensembl; ENST00000338791; ENSP00000345096; ENSG00000106348. [P20839-6]
DR   Ensembl; ENST00000348127; ENSP00000265385; ENSG00000106348. [P20839-3]
DR   Ensembl; ENST00000354269; ENSP00000346219; ENSG00000106348. [P20839-5]
DR   Ensembl; ENST00000419067; ENSP00000399400; ENSG00000106348. [P20839-7]
DR   Ensembl; ENST00000480861; ENSP00000420185; ENSG00000106348. [P20839-4]
DR   Ensembl; ENST00000496200; ENSP00000420803; ENSG00000106348. [P20839-2]
DR   GeneID; 3614; -.
DR   KEGG; hsa:3614; -.
DR   UCSC; uc003vmt.3; human. [P20839-1]
DR   CTD; 3614; -.
DR   DisGeNET; 3614; -.
DR   GeneCards; IMPDH1; -.
DR   GeneReviews; IMPDH1; -.
DR   HGNC; HGNC:6052; IMPDH1.
DR   MalaCards; IMPDH1; -.
DR   MIM; 146690; gene.
DR   MIM; 180105; phenotype.
DR   MIM; 613837; phenotype.
DR   neXtProt; NX_P20839; -.
DR   OpenTargets; ENSG00000106348; -.
DR   Orphanet; 65; Leber congenital amaurosis.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA29862; -.
DR   eggNOG; ENOG410ISZP; Eukaryota.
DR   eggNOG; COG0517; LUCA.
DR   GeneTree; ENSGT00530000062923; -.
DR   HOGENOM; HOG000165752; -.
DR   HOVERGEN; HBG052122; -.
DR   KO; K00088; -.
DR   OMA; DAMEKNN; -.
DR   OrthoDB; EOG091G0EAV; -.
DR   PhylomeDB; P20839; -.
DR   TreeFam; TF300378; -.
DR   BioCyc; MetaCyc:HS02896-MONOMER; -.
DR   BRENDA; 1.1.1.205; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-73817; Purine ribonucleoside monophosphate biosynthesis.
DR   SABIO-RK; P20839; -.
DR   UniPathway; UPA00601; UER00295.
DR   ChiTaRS; IMPDH1; human.
DR   EvolutionaryTrace; P20839; -.
DR   GeneWiki; IMPDH1; -.
DR   GenomeRNAi; 3614; -.
DR   PRO; PR:P20839; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106348; -.
DR   CleanEx; HS_IMPDH1; -.
DR   ExpressionAtlas; P20839; baseline and differential.
DR   Genevisible; P20839; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003938; F:IMP dehydrogenase activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003676; F:nucleic acid binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0006177; P:GMP biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006183; P:GTP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0046651; P:lymphocyte proliferation; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; TAS:Reactome.
DR   CDD; cd00381; IMPDH; 1.
DR   Gene3D; 3.20.20.70; -; 1.
DR   HAMAP; MF_01964; IMPDH; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000644; CBS_dom.
DR   InterPro; IPR005990; IMP_DH.
DR   InterPro; IPR015875; IMP_DH/GMP_Rdtase_CS.
DR   InterPro; IPR001093; IMP_DH_GMPRt.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00478; IMPDH; 1.
DR   PIRSF; PIRSF000130; IMPDH; 1.
DR   SMART; SM00116; CBS; 2.
DR   TIGRFAMs; TIGR01302; IMP_dehydrog; 1.
DR   PROSITE; PS51371; CBS; 2.
DR   PROSITE; PS00487; IMP_DH_GMP_RED; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; CBS domain; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; DNA-binding;
KW   GMP biosynthesis; Leber congenital amaurosis; Metal-binding;
KW   Methylation; NAD; Nucleus; Oxidoreductase; Phosphoprotein; Potassium;
KW   Purine biosynthesis; Reference proteome; Repeat; Retinitis pigmentosa;
KW   RNA-binding.
FT   INIT_MET      1      1       Removed. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156,
FT                                ECO:0000269|PubMed:7903306}.
FT   CHAIN         2    514       Inosine-5'-monophosphate dehydrogenase 1.
FT                                /FTId=PRO_0000093670.
FT   DOMAIN      114    173       CBS 1. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   DOMAIN      179    237       CBS 2. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   NP_BIND     274    276       NAD. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   NP_BIND     324    326       NAD. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   REGION      364    366       IMP binding.
FT   REGION      387    388       IMP binding.
FT   REGION      411    415       IMP binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156}.
FT   ACT_SITE    331    331       Thioimidate intermediate.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   ACT_SITE    429    429       Proton acceptor. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156}.
FT   METAL       326    326       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       328    328       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       331    331       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       500    500       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       501    501       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       502    502       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   BINDING     329    329       IMP.
FT   BINDING     441    441       IMP. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     341    341       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:P50096}.
FT   MOD_RES     355    355       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:P50096}.
FT   VAR_SEQ       1     33       MADYLISGGTGYVPEDGLTAQQLFASADGLTYN -> MEGP
FT                                LTPPPLQGGGAAAVPEPGARQHPGHETAAQRYSARLLQAGY
FT                                EPESPRLDLATHPTTPRSELSSVVLLAGVGVQMDRLRRAS
FT                                (in isoform 7). {ECO:0000305}.
FT                                /FTId=VSP_046968.
FT   VAR_SEQ       1      1       M -> MEGPLTPPPLQGGGAAAVPEPGARQHPGHETAAQRY
FT                                SARLLQAGYEPESM (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014363.
FT   VAR_SEQ       1      1       M -> MEGPLTPPPLQGGGAAAVPEPGARQHPGHETAAQRY
FT                                SARLLQAGYEPESCFLLELSSVVLLAGVGVQMDRLRRASM
FT                                (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046969.
FT   VAR_SEQ       1      1       M -> MEGPLTPPPLQGGGAAAVPEPGARQHPGHETAAQRY
FT                                SARLLQAGYEPESPRLDLATHPTTPRSELSSVVLLAGVGVQ
FT                                MDRLRRASM (in isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_046970.
FT   VAR_SEQ      84    108       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_002674.
FT   VAR_SEQ     104    108       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043485.
FT   VARIANT     105    105       R -> W (in LCA11; does not alter the
FT                                enzymatic affinity of the corresponding
FT                                enzyme; alters the affinity and/or the
FT                                specificity of single-stranded nucleic
FT                                acid). {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065616.
FT   VARIANT     116    116       T -> M (in RP10; does not alter the
FT                                enzymatic affinity of the corresponding
FT                                enzyme; alters the affinity and/or the
FT                                specificity of single-stranded nucleic
FT                                acid). {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065617.
FT   VARIANT     198    198       N -> K (in LCA11; does not alter the
FT                                enzymatic affinity of the corresponding
FT                                enzyme; alters the affinity and/or the
FT                                specificity of single-stranded nucleic
FT                                acid). {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065618.
FT   VARIANT     224    224       R -> P (in RP10).
FT                                {ECO:0000269|PubMed:11875049}.
FT                                /FTId=VAR_017031.
FT   VARIANT     226    226       D -> N (in RP10).
FT                                {ECO:0000269|PubMed:11875050,
FT                                ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_017032.
FT   VARIANT     268    268       V -> I (in RP10).
FT                                {ECO:0000269|PubMed:11875050,
FT                                ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_017033.
FT   VARIANT     285    285       A -> T. {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065619.
FT   VARIANT     324    324       G -> D (does not alter the enzymatic
FT                                affinity of the corresponding enzyme;
FT                                does not affect the affinity for single-
FT                                stranded nucleic acid).
FT                                {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065620.
FT   VARIANT     372    372       H -> P (in RP10; alters the affinity and/
FT                                or the specificity of single-stranded
FT                                nucleic acid).
FT                                {ECO:0000269|PubMed:16384941}.
FT                                /FTId=VAR_065621.
FT   CONFLICT     29     29       G -> D (in Ref. 1; AAA36114).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       K -> N (in Ref. 1; AAA36114).
FT                                {ECO:0000305}.
FT   CONFLICT    273    274       LD -> FH (in Ref. 1; AAA36114).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       A -> P (in Ref. 1; AAA36114).
FT                                {ECO:0000305}.
FT   CONFLICT    497    497       A -> P (in Ref. 1; AAA36114).
FT                                {ECO:0000305}.
FT   STRAND       12     14       {ECO:0000244|PDB:1JCN}.
FT   HELIX        20     23       {ECO:0000244|PDB:1JCN}.
FT   STRAND       26     28       {ECO:0000244|PDB:1JCN}.
FT   HELIX        32     34       {ECO:0000244|PDB:1JCN}.
FT   STRAND       35     37       {ECO:0000244|PDB:1JCN}.
FT   HELIX        46     48       {ECO:0000244|PDB:1JCN}.
FT   STRAND       53     58       {ECO:0000244|PDB:1JCN}.
FT   STRAND       60     63       {ECO:0000244|PDB:1JCN}.
FT   STRAND       65     67       {ECO:0000244|PDB:1JCN}.
FT   TURN         71     73       {ECO:0000244|PDB:1JCN}.
FT   HELIX        76     84       {ECO:0000244|PDB:1JCN}.
FT   STRAND       88     91       {ECO:0000244|PDB:1JCN}.
FT   HELIX        97    108       {ECO:0000244|PDB:1JCN}.
FT   STRAND      142    144       {ECO:0000244|PDB:1JCN}.
FT   TURN        160    163       {ECO:0000244|PDB:1JCN}.
FT   TURN        195    199       {ECO:0000244|PDB:1JCN}.
FT   HELIX       200    204       {ECO:0000244|PDB:1JCN}.
FT   STRAND      211    216       {ECO:0000244|PDB:1JCN}.
FT   STRAND      247    250       {ECO:0000244|PDB:1JCN}.
FT   HELIX       256    265       {ECO:0000244|PDB:1JCN}.
FT   STRAND      269    273       {ECO:0000244|PDB:1JCN}.
FT   HELIX       281    293       {ECO:0000244|PDB:1JCN}.
FT   STRAND      298    304       {ECO:0000244|PDB:1JCN}.
FT   HELIX       307    316       {ECO:0000244|PDB:1JCN}.
FT   STRAND      319    323       {ECO:0000244|PDB:1JCN}.
FT   HELIX       343    354       {ECO:0000244|PDB:1JCN}.
FT   HELIX       355    357       {ECO:0000244|PDB:1JCN}.
FT   STRAND      361    365       {ECO:0000244|PDB:1JCN}.
FT   HELIX       370    378       {ECO:0000244|PDB:1JCN}.
FT   STRAND      382    387       {ECO:0000244|PDB:1JCN}.
FT   TURN        388    392       {ECO:0000244|PDB:1JCN}.
FT   HELIX       453    471       {ECO:0000244|PDB:1JCN}.
FT   HELIX       476    484       {ECO:0000244|PDB:1JCN}.
FT   STRAND      490    492       {ECO:0000244|PDB:1JCN}.
SQ   SEQUENCE   514 AA;  55406 MW;  ABAC654A9091BE62 CRC64;
     MADYLISGGT GYVPEDGLTA QQLFASADGL TYNDFLILPG FIDFIADEVD LTSALTRKIT
     LKTPLISSPM DTVTEADMAI AMALMGGIGF IHHNCTPEFQ ANEVRKVKKF EQGFITDPVV
     LSPSHTVGDV LEAKMRHGFS GIPITETGTM GSKLVGIVTS RDIDFLAEKD HTTLLSEVMT
     PRIELVVAPA GVTLKEANEI LQRSKKGKLP IVNDCDELVA IIARTDLKKN RDYPLASKDS
     QKQLLCGAAV GTREDDKYRL DLLTQAGVDV IVLDSSQGNS VYQIAMVHYI KQKYPHLQVI
     GGNVVTAAQA KNLIDAGVDG LRVGMGCGSI CITQEVMACG RPQGTAVYKV AEYARRFGVP
     IIADGGIQTV GHVVKALALG ASTVMMGSLL AATTEAPGEY FFSDGVRLKK YRGMGSLDAM
     EKSSSSQKRY FSEGDKVKIA QGVSGSIQDK GSIQKFVPYL IAGIQHGCQD IGARSLSVLR
     SMMYSGELKF EKRTMSAQIE GGVHGLHSYE KRLY
//
